IQV Stock Recent News

The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation.

The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.

UPPER NYACK, N.Y.--(BUSINESS WIRE)--When pharmacists can't give adult vaccinations, millions of people go without them.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences and healthcare industries, today announced that IQVIA AI Assistant has been awarded a 2024 PM360 Innovation Award in the Artificial Intelligence category. Launched in September 2024, IQVIA AI Assistant revolutionizes insight generation by providing rapid, relevant and precise answers to complex business questio.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the TD Cowen Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a lead.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has published its 2024 Sustainability Report. The report details IQVIA's sustainability achievements consistent with its mission to accelerate innovation for a healthier world. “IQVIA combines technology and scientific expertise with our unique information assets and Healthcare-gr.

ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.

IQVIA has seen an increase of 58.97% in its revenues since 2017. In addition, its net profit margin has strengthened since 2018. The CRO market expects to grow at a 7.42% CAGR between 2024 and 2033, which indicates that the Research & Development Solutions segment of IQVIA will have a positive outlook. IQVIA has an enormous dataset, with 1,200 million registers. This dataset has been crucial for developing artificial intelligence and data analytics solutions in the upcoming years.

Explore how IQVIA's (IQV) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.